

# Muhammad Zubair Israr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7713017/publications.pdf>

Version: 2024-02-01

32  
papers

748  
citations

623734

14  
h-index

526287

27  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trimethylamine N-oxide and prognosis in acute heart failure. <i>Heart</i> , 2016, 102, 841-848.	2.9	195
2	Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction. <i>Clinical Chemistry</i> , 2017, 63, 420-428.	3.2	120
3	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	7.1	68
4	Modulation of cardiac fibrosis by KrÄppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. <i>Cardiovascular Research</i> , 2015, 107, 420-430.	3.8	37
5	Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2159-2162.	1.8	32
6	Ethnic differences in association of outcomes with trimethylamine N-oxide in acute heart failure patients. <i>ESC Heart Failure</i> , 2020, 7, 2373-2378.	3.1	27
7	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , 2019, 21, 1291-1294.	7.1	25
8	Association of gut-related metabolites with outcome in acute heart failure. <i>American Heart Journal</i> , 2021, 234, 71-80.	2.7	25
9	Matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS): basics and clinical applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 883-896.	2.3	23
10	The Gut Axis Involvement in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 23-31.	2.1	21
11	Indomethacin reduces rates of aortic dissection and rupture of the abdominal aorta by inhibiting monocyte/macrophage accumulation in a murine model. <i>Scientific Reports</i> , 2019, 9, 10751.	3.3	19
12	Proteomic Biomarkers of Heart Failure. <i>Heart Failure Clinics</i> , 2018, 14, 93-107.	2.1	17
13	Prognostic Role of Molecular Forms of B-Type Natriuretic Peptide in Acute Heart Failure. <i>Clinical Chemistry</i> , 2017, 63, 880-886.	3.2	16
14	Mass spectrometry in medicine: a technology for the future?. <i>Future Science OA</i> , 2017, 3, FSO213.	1.9	16
15	Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 397-413.	2.1	15
16	Processed B-Type Natriuretic Peptide Is a Biomarker of Postinterventional Restenosis in Ischemic Heart Disease. <i>Clinical Chemistry</i> , 2013, 59, 1330-1337.	3.2	14
17	Circulating interleukin-6 (IL-6) levels are associated with aortic dimensions in genetic aortic conditions. <i>PLoS ONE</i> , 2019, 14, e0214084.	2.5	12
18	Impact of acute choline loading on circulating trimethylamine N-oxide levels. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1899-1902.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure. <i>European Journal of Preventive Cardiology</i> , 2020, 28, e28-e31.	1.8	12
20	Biomarkers in Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 223-243.	2.1	10
21	Implications of serial measurements of natriuretic peptides in heart failure: insights from <sc>BIOSTAT-CHF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1486-1490.	7.1	7
22	B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction. <i>American Heart Journal</i> , 2018, 200, 37-43.	2.7	6
23	Association of gut-related metabolites with respiratory symptoms in COVID-19: A proof-of-concept study. <i>Nutrition</i> , 2022, 96, 111585.	2.4	6
24	Surrogate markers of gut dysfunction are related to heart failure severity and outcome from the BIOSTAT-CHF consortium. <i>American Heart Journal</i> , 2022, 248, 108-119.	2.7	5
25	Biomarkers of Heart Failure: Past, Present, and Future. <i>Heart Failure Clinics</i> , 2018, 14, ix-x.	2.1	3
26	Biomarkers in Cardiovascular Disease: The Dilemma of Racial Differences. <i>Journal of the American Heart Association</i> , 2019, 8, e014295.	3.7	2
27	Gut Feeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1967-1969.	2.4	2
28	Targeting the gut microbiome in coronary artery disease. <i>American Heart Journal</i> , 2021, 236, 1-3.	2.7	1
29	In Reply. <i>Clinical Chemistry</i> , 2017, 63, 1046-1047.	3.2	0
30	Aortic dissection—a contemporary revisit of an autopsy series. <i>American Heart Journal</i> , 2019, 209, 106-107.	2.7	0
31	In reply: The emerging value of molecular forms of B-type natriuretic peptide in heart failure. <i>Journal of Laboratory and Precision Medicine</i> , 0, 2, 62-62.	1.1	0
32	Serial measurements of natriuretic peptide to assess pharmacological interventions and subsequent impact on cardiovascular risk stratification in heart failure: a precision medicine approach. <i>Journal of Laboratory and Precision Medicine</i> , 0, 2, 17-17.	1.1	0